The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Optimizing the selection between available JAK inhibitors in myelofibrosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the optimization of selecting between JAK inhibitors for treating myelofibrosis. He notes the differences between the four approved JAK inhibitors and highlights that the choice of inhibitor should be guided by the patient’s specific condition and response to treatment, with ruxolitinib demonstrating the most pronounced survival benefit. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research support: Incyte, BMS, CTI (Sobi), Morphosys, Karyopharm, Sumitomo, Ajax, Disc, Ionis, Geron, Janssen, Cogent, Blueprint, Kartos, Telios.; Honoraria/consulting fees: Incyte, BMS, CTI (Sobi), GSK, Abbvie, Morphosys, Pharma Essentia, Sumitomo, Karyopharm, Ionis, Disc, Geron, Morphic, Jubilant, Ono, Novartis, Blueprint, Cogent.
